Chonnam Med J.  1999 Jun;35(2):275-279.

The Effects of Sulodexide(Oral Heparin) in Coronary Stented Patients

• Jeong MH
• Cho JG
• Bom HS
• Ahn YK
• Cho DH
• Park CM
• Park WS
• Kim NH
• Kim JW
• Kim SH
• Cho JH
• Park JC
• Kang JC

Abstract

The purpose of this study was to determine the long-term clinical efficacy and safety of sulodexide on coronary stented patients. From October 1997, 137 patients who had underwent coronary stent implantation and taken a sulodexide (oral heparin: Vesseldue ) 450 LRU (lipoprotein-lipase-releasing unit) 3 capsules per day orally for 1 to 6 months were included and compared with control group, in which follow-up coronary angiography was done among stented patients not treated which sulodexide, during the same period as sulodexide treated group. Combinated antiplatelet agents were limited to aspirin and ticlopidine, or aspirin and cilostazol. During follow-up, there were no significant bleeding complications or specific side effects. Prothrombin time and activated partial thrombonplastin time was not changed. Acute or subacute stent(PT) thrombosis was observed in 3 patients(APTT) (2.1%), but fatal myocardial infractions or deaths were not appeared. Among 52 patients who underwent follow-up coronary angiography, significant stent restenosis was developed in 12 patients (23.1%). In conclusion, sulodexide combined with antiplatelet agents is safe and effective in preventing the acute and subacute thrombosis. Further study is necessary to document the effect of sulodexide in preventing restenosis.

Keyword

Stent; Oral Heparin

MeSH Terms

Aspirin
Capsules
Coronary Angiography
Follow-Up Studies
Hemorrhage
Heparin
Humans
Platelet Aggregation Inhibitors
Prothrombin Time
Stents*
Thrombosis
Ticlopidine
Aspirin
Capsules
Heparin
Platelet Aggregation Inhibitors
Ticlopidine